These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 23614904)

  • 1. Bile acid and sterol metabolism with combined HMG-CoA reductase and PCSK9 suppression.
    Parker RA; Garcia R; Ryan CS; Liu X; Shipkova P; Livanov V; Patel P; Ho SP
    J Lipid Res; 2013 Sep; 54(9):2400-9. PubMed ID: 23614904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Proprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates.
    Liang H; Chaparro-Riggers J; Strop P; Geng T; Sutton JE; Tsai D; Bai L; Abdiche Y; Dilley J; Yu J; Wu S; Chin SM; Lee NA; Rossi A; Lin JC; Rajpal A; Pons J; Shelton DL
    J Pharmacol Exp Ther; 2012 Feb; 340(2):228-36. PubMed ID: 22019884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9.
    Rashid S; Curtis DE; Garuti R; Anderson NN; Bashmakov Y; Ho YK; Hammer RE; Moon YA; Horton JD
    Proc Natl Acad Sci U S A; 2005 Apr; 102(15):5374-9. PubMed ID: 15805190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulation of the proprotein convertase subtilisin/kexin type 9 in intestinal epithelial cells.
    Leblond F; Seidah NG; Précourt LP; Delvin E; Dominguez M; Levy E
    Am J Physiol Gastrointest Liver Physiol; 2009 Apr; 296(4):G805-15. PubMed ID: 19179626
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Circulating proprotein convertase subtilisin kexin type 9 has a diurnal rhythm synchronous with cholesterol synthesis and is reduced by fasting in humans.
    Persson L; Cao G; Ståhle L; Sjöberg BG; Troutt JS; Konrad RJ; Gälman C; Wallén H; Eriksson M; Hafström I; Lind S; Dahlin M; Amark P; Angelin B; Rudling M
    Arterioscler Thromb Vasc Biol; 2010 Dec; 30(12):2666-72. PubMed ID: 20884874
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Short-term impact of low-dose atorvastatin on serum proprotein convertase subtilisin/kexin type 9.
    Guo YL; Liu J; Xu RX; Zhu CG; Wu NQ; Jiang LX; Li JJ
    Clin Drug Investig; 2013 Dec; 33(12):877-83. PubMed ID: 24114461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes.
    Zhang L; McCabe T; Condra JH; Ni YG; Peterson LB; Wang W; Strack AM; Wang F; Pandit S; Hammond H; Wood D; Lewis D; Rosa R; Mendoza V; Cumiskey AM; Johns DG; Hansen BC; Shen X; Geoghagen N; Jensen K; Zhu L; Wietecha K; Wisniewski D; Huang L; Zhao JZ; Ernst R; Hampton R; Haytko P; Ansbro F; Chilewski S; Chin J; Mitnaul LJ; Pellacani A; Sparrow CP; An Z; Strohl W; Hubbard B; Plump AS; Blom D; Sitlani A
    Int J Biol Sci; 2012; 8(3):310-27. PubMed ID: 22355267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transintestinal cholesterol excretion is an active metabolic process modulated by PCSK9 and statin involving ABCB1.
    Le May C; Berger JM; Lespine A; Pillot B; Prieur X; Letessier E; Hussain MM; Collet X; Cariou B; Costet P
    Arterioscler Thromb Vasc Biol; 2013 Jul; 33(7):1484-93. PubMed ID: 23559630
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bile acids and lipoprotein metabolism: effects of cholestyramine and chenodeoxycholic acid on human hepatic mRNA expression.
    Nilsson LM; Abrahamsson A; Sahlin S; Gustafsson U; Angelin B; Parini P; Einarsson C
    Biochem Biophys Res Commun; 2007 Jun; 357(3):707-11. PubMed ID: 17448444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Statins upregulate PCSK9, the gene encoding the proprotein convertase neural apoptosis-regulated convertase-1 implicated in familial hypercholesterolemia.
    Dubuc G; Chamberland A; Wassef H; Davignon J; Seidah NG; Bernier L; Prat A
    Arterioscler Thromb Vasc Biol; 2004 Aug; 24(8):1454-9. PubMed ID: 15178557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cholesterol-lowering effects and potential mechanisms of different polar extracts from Cyclocarya paliurus leave in hyperlipidemic mice.
    Jiang C; Wang Q; Wei Y; Yao N; Wu Z; Ma Y; Lin Z; Zhao M; Che C; Yao X; Zhang J; Yin Z
    J Ethnopharmacol; 2015 Dec; 176():17-26. PubMed ID: 26477373
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy.
    McKenney JM; Koren MJ; Kereiakes DJ; Hanotin C; Ferrand AC; Stein EA
    J Am Coll Cardiol; 2012 Jun; 59(25):2344-53. PubMed ID: 22463922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peroxisome Proliferator-activated receptor γ activation by ligands and dephosphorylation induces proprotein convertase subtilisin kexin type 9 and low density lipoprotein receptor expression.
    Duan Y; Chen Y; Hu W; Li X; Yang X; Zhou X; Yin Z; Kong D; Yao Z; Hajjar DP; Liu L; Liu Q; Han J
    J Biol Chem; 2012 Jul; 287(28):23667-77. PubMed ID: 22593575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proprotein convertase subtilisin/kexin 9 inhibitors: an emerging lipid-lowering therapy?
    Dragan S; Serban MC; Banach M
    J Cardiovasc Pharmacol Ther; 2015 Mar; 20(2):157-68. PubMed ID: 24938457
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Strong induction of PCSK9 gene expression through HNF1alpha and SREBP2: mechanism for the resistance to LDL-cholesterol lowering effect of statins in dyslipidemic hamsters.
    Dong B; Wu M; Li H; Kraemer FB; Adeli K; Seidah NG; Park SW; Liu J
    J Lipid Res; 2010 Jun; 51(6):1486-95. PubMed ID: 20048381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergic hypocholesterolaemic effect of n-3 PUFA and oestrogen by modulation of hepatic cholesterol metabolism in female rats.
    Oh Y; Jin Y; Park Y
    Br J Nutr; 2015 Dec; 114(11):1766-73. PubMed ID: 26388416
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The PCSK9 decade.
    Lambert G; Sjouke B; Choque B; Kastelein JJ; Hovingh GK
    J Lipid Res; 2012 Dec; 53(12):2515-24. PubMed ID: 22811413
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic overexpression of idol increases circulating protein convertase subtilisin/kexin type 9 in mice and hamsters via dual mechanisms: sterol regulatory element-binding protein 2 and low-density lipoprotein receptor-dependent pathways.
    Sasaki M; Terao Y; Ayaori M; Uto-Kondo H; Iizuka M; Yogo M; Hagisawa K; Takiguchi S; Yakushiji E; Nakaya K; Ogura M; Komatsu T; Ikewaki K
    Arterioscler Thromb Vasc Biol; 2014 Jun; 34(6):1171-8. PubMed ID: 24675665
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterol.
    Welder G; Zineh I; Pacanowski MA; Troutt JS; Cao G; Konrad RJ
    J Lipid Res; 2010 Sep; 51(9):2714-21. PubMed ID: 20525997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.